Looking to highlight a funding opportunity? Please send a brief description, link, and deadline to firstname.lastname@example.org
State & Federal Programs
The National Cancer Institute (NCI) announces the availability of a funding opportunity aimed at accelerating the development and commercialization of highly innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. This Program Announcement complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating a path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches. Click here to learn more.
Receipt Dates: May 28, 2014; November 4, 2014; May 27, 2015; November 4, 2015; May 27, 2016
Deadline: November 2, 2015
The MassCEC Catalyst Program, which is funded by MassCEC and managed by the Massachusetts Technology Transfer Center (MTTC), awards early-stage researchers grant awards up to $40,000 to help demonstrate the commercial viability of their clean energy technology.
Also, under the Catalyst Water Challenge, MassCEC will provide funding and technical support for projects that deploy water innovation technologies or innovative combinations of existing technologies.
Deadline: October 30, 2015
The MA Innovation Commercialization Seed Fund is intended to support the demonstration of the commercialization viability of a technology developed at a Massachusetts university.
To be eligible for an award, applicants must be a Principal Investigator with technology disclosed to your host institution. Your host institution must be a university in Massachusetts. PIs from UMass are not eligible to apply, as the MTTC Innovation Commercialization Seed Fund has already been launched separately for UMass applicants.
Deadline: October 28, 2015
The Michael J. Fox Foundation works tirelessly to accelerate promising research toward breakthroughs for Parkinson’s patients. While our strong emphasis is on funding translational and clinical research, we also support high-risk/high-reward discovery work. In addition to funding, awardees benefit from working with our internal research staff and broad network of scientific and industry advisors.
Core funding program opportunities include Target Advancement, Therapeutic Development, and Outcome Measures.
Deadline: No deadline; applications accepted anytime
One-year grants to jump start new ideas in PD research. The Rapid Response Innovation Awards (RRIA) program supports high-risk, high-reward projects with little-to-no existing preliminary data, but with potential to significantly impact our understanding of Parkinson’s disease. Moreover, this program is well-suited for early exploratory studies that may open the field up to new targets or pathways that may ultimately feed the early drug development pipeline for a treatment of PD.
There is no deadline to apply; submit an Expressions of Interest here.
DELSIA is an independent nonprofit venture philanthropy affiliate of the autism research and advocacy foundation Autism Speaks. DELSIA provides funds to for-profit partners to advance the development of products that address unmet medical and behavioral health needs of the autism community. It was created as an innovative funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by ensuring that scientific breakthroughs and technological advances are developed into products that improve health and quality of life for individuals with autism and their families. Our purpose is to transform lives by serving as a catalyst to facilitate and accelerate the delivery and availability of impactful products.